Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical testing and is currently being evaluated in a Phase 1/2-3 clinical study.

In the study, the safety, toxicology and pharmacokinetics of IB1001 were evaluated in animal models and compared to commercially available Factor IX products. Results showed that IB1001 has an excellent safety profile in animal models and a similar pharmacokinetic profile when compared to currently available Factor IX products.

"These results and the progress that we have made in advancing our protein manufacturing technology have facilitated the advancement of IB1001 into a Phase 1/2-3 clinical program," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia around the world. We expect to move IB1001 into a pivotal trial and look forward to updating you on all developments related to this program."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder cause
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... the world's largest provider of surgical instruments to the Spine Industry. The acquisition ...
(Date:7/1/2015)... RESEARCH TRIANGLE PARK, N.C. and ... -- Leading agricultural research firm AgBiome, and Genective, key ... partnership to accelerate the discovery of new generations ... new traits for insect control to counter the ... to partner with Genective, aligning AgBiome,s unique insect ...
(Date:7/1/2015)... , ... July 01, 2015 , ... The next-generation sequencing ... key market segments, including the molecular diagnostics industry. BCC Research reveals in its new ... NGS-based tests, lower test costs, and a growing need for better diagnostics as part ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... Ariadne, a leader in bioinformatics software and knowledge ... site license for the use of Pathway Studio® ... applying innovative technologies, Georgetown Lombardi Comprehensive Cancer Center ... their efforts to unravel cancer disease biology, disease ...
... Qteros, Inc., the developer of a unique ... for the lowest-cost production of cellulosic ethanol, today announced ... and Europe for members of its senior management team. ... Development and Engineering, will present on a panel entitled, ...
... new combination of nanoparticles and graphene results in a more ... today online at the Journal of the American Chemical Society. ... active as well. The researchers are confident the results will ... important area of energy technology, but cost and durability are ...
Cached Biology Technology:Georgetown Lombardi Comprehensive Cancer Center Taps Ariadne for G-DOC Pathway Data and Tools 2Georgetown Lombardi Comprehensive Cancer Center Taps Ariadne for G-DOC Pathway Data and Tools 3Qteros Management to Present at Notable Alternative Energy Conferences in February 2A paperweight for platinum 2A paperweight for platinum 3
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... Harrison, Director of the School of Policy Studies at ... this week at an international think tank on "The ... Nunavut. The Canada-UK Colloquium is organized annually ... in Britain, to generate discussion and research about issues ...
... headed by Llus Ribas de Pouplana, ICREA professor at the ... as "Paper of the week" in the December issue of ... available online. The article describes the discovery of a new ... that is crucial for mitochondria. The removal of SLIMP in ...
... Energy Biosciences Institute (EBI) in Berkeley projects that ... much more long-term research, development and demonstration. In ... serve to advance the nascent industry. "Even ... cultivation to harvesting to processing), algae oil production ...
Cached Biology News:Scientists at IRB Barcelona discover a new protein critical for mitochondria 2Algae for biofuels: Moving from promise to reality, but how fast? 2Algae for biofuels: Moving from promise to reality, but how fast? 3Algae for biofuels: Moving from promise to reality, but how fast? 4
... score SNPs, Polymorphic uses proven, validated Sanger ... DNA analysis. We use high throughput capillary ... confirmed by sequencing in both directions. The ... context information, further confirming the location of ...
... Model 96 and PowerPac basic power supply are ... acids in agarose gels. This Model 96 cell ... cm UV-transparent gel tray with fluorescent ruler, and ... 100-120 and 220-240 V, provides output of 10-300 ...
... and PowerPac basic power supply are used for ... agarose gels. The mini format cell includes a ... leveling bubble. The PowerPac basic power supply, 100-120 ... 4-400 mA, and 75 W. Power cord and ...
... mini ReadySub-Cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The wide ... with cables and electrodes, and leveling bubble. The ... provides output of 10-300 V, 4-400 mA, and ...
Biology Products: